

ADLINE CHEM LAB LIMITED

[Formerly Kamron Laboratories Limited]

Registered Office : 904, Shapath-1, Opp. Rajpath Club, S. G. Highway,

Ahmedabad – 380 054, Gujarat, INDIA. Phone: +91-9227510541

E-mail : info@kamronlabs.in Website: www.kamronlabs.com

CIN : L24231GJ1988PLC010956



14th August, 2023

BSE Limited

Phiroze Jeejeebhoy Towers,

Dalal Street, Fort,

Mumbai - 400 001

Company Code No. 524604

Dear Sirs,

Sub: - Outcome of Board Meeting

- Submission of Un-audited Financial Results for the Quarter ended on 30th June, 2023

Please note that the Board of Directors in their meeting held today, have taken on record the Unaudited Financial Results for the quarter ended on 30th June, 2023.

We are enclosing herewith copy of the said Unaudited Financial Results for the quarter ended on 30th June, 2023 along with Limited Review Report thereon.

This is as per Regulation – 33 of the SEBI (LODR) Regulations, 2015.

The meeting of Board of Directors was commenced at 4.00 PM and concluded at 5.55 PM.

Thanking you,

Yours faithfully,

For ADLINE CHEM LAB LIMITED

(Formerly Known as Kamron Laboratories Limited)

KAMLESH J. LASKARI

MANAGING DIRECTOR

(DIN: 00461198)

Encl: As above.

ADLINE CHEM LAB LIMITED

[Formerly Kamron Laboratories Limited]

Registered Office : 904, Shapath-1, Opp. Rajpath Club, S. G. Highway,

Ahmedabad – 380 054, Gujarat, INDIA. Phone: +91-9227510541

E-mail : info@kamronlabs.in Website: www.kamronlabs.com

CIN : L24231GJ1988PLC010956



STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED ON 30TH JUNE, 2023

(Rs. In lakh)

Particulars		Quarter ended on			Previous Year ended on 31-03-2023
		30-06-2023	31-03-2023	30-06-2022	
(Refer Notes Below)		(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	Revenue from operations	-	-	-	-
2	Other income	-	7.47	0.15	99.51
3	Total Income (1+2)	-	7.47	0.15	99.51
4	Expenses				
	a. Cost of Materials consumed	-	-	-	-
	b. Purchases of stock-in-trade	-	-	-	-
	c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	25.90
	d. Employee benefits expense	1.70	1.10	1.74	5.04
	e. Finance costs	-	-	-	-
	f. Depreciation & amortisation expense	-	-	8.75	8.75
	g. Other expenses	6.48	7.69	(0.45)	48.73
	Total Expenses	8.18	8.79	10.04	88.42
5	Profit / (Loss) before exceptional items and tax (3-4)	(8.18)	(1.32)	(9.89)	11.09
6	Exceptional items	-	-	-	-
	Loss on technical know how W/off	-	-	-	409.99
	Loss on trademark W/off	-	-	-	24.51
	Depreciation Written back	-	-	-	-
7	Profit / (Loss) before tax (5-6)	(8.18)	(1.32)	(9.89)	(423.41)
8	Tax expense:				
	Current tax	-	-	-	-
	Deferred tax	-	-	-	-
	Short/(Excess)Provision of Income Tax of earlier years	-	-	-	-
9	Profit (Loss) for the period from continuing operations (7-8)	(8.18)	(1.32)	(9.89)	(423.41)
10	Profit/(loss) from discontinuing operations before Tax	-	-	-	-
11	Tax expense of discontinuing operations	-	-	-	-
12	Profit/(loss) from Discontinuing operations (after tax) (10-11)	-	-	-	-
13	Profit / (Loss) for the period (9+12)	(8.18)	(1.32)	(9.89)	(423.41)

ADLINE CHEM LAB LIMITED

[Formerly Kamron Laboratories Limited]

Registered Office : 904, Shapath-1, Opp. Rajpath Club, S. G. Highway,

Ahmedabad – 380 054, Gujarat, INDIA. Phone: +91-9227510541

E-mail : info@kamronlabs.in Website: www.kamronlabs.com

CIN : L24231GJ1988PLC010956



Particulars		Quarter ended on			Previous Year ended on 31-03-2023
		30-06-2023	31-03-2023	30-06-2022	
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
14	Other Comprehensive Income				
	<i>Items that will not be reclassified subsequently to profit or loss</i>				
	Re-measurement of defined benefit plans	-	-	-	-
	Tax expense on above item	-	-	-	-
	Revaluation of Land	-	-	-	-
	Tax expense on above item	-	-	-	-
	Income tax relating to items that will not be reclassified to profit or loss				
	<i>Items that will be reclassified subsequently to profit or loss</i>				
	Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
	Other Comprehensive Income, net of tax				
15	Total Comprehensive Income for the period (13+14)	(8.18)	(1.32)	(9.89)	(423.41)
16	Paid-up equity shares capital (Face Value per share Rs. 10/-)	585.00	585.00	585.00	585.00
17	Reserves excluding Revaluation Reserves				(741.75)
18	Earnings Per Share of Rs. 10/- each (for continuing operations)				
	- Basic	(0.14)	(0.02)	(0.17)	(7.24)
	- Diluted	(0.14)	(0.02)	(0.17)	(7.24)
19	Earnings Per Share of Rs. 10/- each (for discontinued operations)				
	- Basic	-	-	-	-
	- Diluted	-	-	-	-
20	Earnings Per Share of Rs. 10/- each (for discontinued & continuing operations)				
	- Basic	(0.14)	(0.02)	(0.17)	(7.24)
	- Diluted	(0.14)	(0.02)	(0.17)	(7.24)

ADLINE CHEM LAB LIMITED

[Formerly Kamron Laboratories Limited]

Registered Office : 904, Shapath-1, Opp. Rajpath Club, S. G. Highway,
Ahmedabad – 380 054, Gujarat, INDIA. Phone: +91-9227510541

E-mail : info@kamronlabs.in Website: www.kamronlabs.com

CIN : L24231GJ1988PLC010956




Notes:

1	The Company is operating only in one segment i.e. Pharmaceutical products. Hence segment reporting is not given as per last report.
2	The Company has associates with Centis Lifecare Pvt Ltd. And Kamron Healthcare Pvt. Ltd.
3	Provision for taxation/deferred taxation, if any, will be made at the year end.
4	Figures, wherever required, are regrouped / rearranged.
5	The above results have been reviewed by audit committee and approved by Board of Directors of Company at its meeting held on 14 th August, 2023
6	The figures for quarter ended on 31 st March, 2023 are the balancing figures between the audited figures in respect of the full financial year ended on 31 st March, 2023 and the year to date figures up to the third quarter of the financial year 2022-23.

For ADLINE CHEM LAB LIMITED
(Formerly Known as Kamron Laboratories Limited)

KAMLESH J. LASKARI
MANAGING DIRECTOR
(DIN:00461198)

Date: 14th August, 2023
Place: Ahmedabad



DEEPAK SONI & ASSOCIATES CHARTERED ACCOUNTANTS

5, Jayshree Apartment, Udhyan Marg, Near Law Garden,
Ahmedabad, Gujarat, India-380006
Phone: (0) 26425150

14th Aug, 2023

Review report to Adline Chem Lab Limited

We have reviewed the accompanying statement of unaudited standalone financial results of Adline Chem Lab Limited for the period ended 30th June 2023, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), 2015, as amended ("the Listing Regulations").

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors of the Company, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement(s). A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Ahmedabad
Date : 14th Aug 2023

FOR DEEPAK SONI & ASSOCIATES
CHARTERED ACCOUNTANTS

FRN: 102250W



Deepak Soni

(Proprietor)

Deepak Soni

M. No. 031138

UDIN: 2331138BQYSKY5808